Ameriprise
CRBU icon

Ameriprise’s Caribou Biosciences CRBU Stock Holding History

Ameriprise’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$52K Buy
29,530
+100
+0.3% +$198 ﹤0.01% 4061
2026
Q1 		$55.9K Sell
29,430
-55,674
-65% -$95.6K ﹤0.01% 3998
2025
Q4 		$135K Sell
85,104
-250
-0.3% -$525 ﹤0.01% 3973
2025
Q3 		$199K Sell
85,354
-223,601
-72% -$422K ﹤0.01% 3902
2025
Q2 		$389K Sell
308,955
-99,103
-24% -$97.5K ﹤0.01% 3611
2025
Q1 		$373K Hold
408,058
– – ﹤0.01% 3605
2024
Q4 		$649K Buy
+408,058
New +$821K ﹤0.01% 3424
2024
Q2 		– Sell
-36,555
Closed -$188K – 3876
2024
Q1 		$188K Buy
36,555
+4
+0% +$25 ﹤0.01% 3700
2023
Q4 		$209K Sell
36,551
-5,825
-14% -$28.8K ﹤0.01% 3714
2023
Q3 		$203K Sell
42,376
-58,495
-58% -$363K ﹤0.01% 3700
2023
Q2 		$429K Buy
100,871
+63,119
+167% +$284K ﹤0.01% 3494
2023
Q1 		$200K Buy
37,752
+875
+2% +$5.45K ﹤0.01% 3730
2022
Q4 		$237K Sell
36,877
-1,315
-3% -$11.7K ﹤0.01% 3665
2022
Q3 		$403K Buy
+38,192
New +$356K ﹤0.01% 3472

Other funds holding CRBU

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Ameriprise's CRBU Position: Q2 2026 in Review

Ameriprise increased its Caribou Biosciences (CRBU) stake by 0.34% in Q2 2026, buying an estimated $198 and bringing the position to 29,530 shares worth $52K. The position accounts for ﹤0.01% of the portfolio, ranked #4061.

Ameriprise first reported a position in CRBU in Q3 2022 and has held it in 14 quarters since. The position peaked at $649K in Q4 2024. 137 funds tracked by Wall St. Rank hold CRBU as of Q2 2026.

  • Ameriprise held 29,530 shares of Caribou Biosciences worth $52K as of Q2 2026.
  • Ameriprise bought 100 Caribou Biosciences shares in Q2 2026, an estimated $198.
  • Caribou Biosciences made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #4061 holding.
  • Ameriprise first reported a position in Caribou Biosciences in Q3 2022 and has held it in 14 quarters since.
  • Ameriprise's Caribou Biosciences position peaked at $649K in Q4 2024.
  • 137 funds tracked by Wall St. Rank held Caribou Biosciences as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.